Nuclear translocation of 3′-phosphoinositide-dependent protein kinase 1 (PDK-1): A potential regulatory mechanism for PDK-1 function

per Lim, Mei A., Kikani, Chintan K., Wick, Michael J., Dong, Lily Q.
Publicat 2003

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor

per Yu, Yi, Hall, Terence, Eathiraj, Sudharshan, Wick, Michael J., Schwartz, Brian, Abbadessa, Giovanni
Publicat a Anticancer Drugs (2017)

Phosphorylation of protein kinase N by phosphoinositide-dependent protein kinase-1 mediates insulin signals to the actin cytoskeleton

per Dong, Lily Q., Landa, Luis R., Wick, Michael J., Zhu, Li, Mukai, Hideyuki, Ono, Yoshitaka, Liu, Feng
Publicat 2000

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

per Yu, Yi, Savage, Ronald E., Eathiraj, Sudharshan, Meade, Justin, Wick, Michael J., Hall, Terence, Abbadessa, Giovanni, Schwartz, Brian
Publicat a PLoS One (2015)

Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma

per Mandelbaum, Joseph, Shestopalov, Ilya A., Henderson, Rachel E., Chau, Nicole G., Knoechel, Birgit, Wick, Michael J., Zon, Leonard I.
Publicat a J Exp Med (2018)

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

per Hidalgo, Manuel, Bruckheimer, Elizabeth, Rajeshkumar, N.V., Garrido-Laguna, Ignacio, De Oliveira, Elizabeth, Rubio-Viqueira, Belen, Strawn, Steven, Wick, Michael J., Martell, James, Sidransky, David
Publicat a Mol Cancer Ther (2011)

Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft

per Morelli, M. Pia, Calvo, Emiliano, Ordoñez, Esther, Wick, Michael J., Viqueira, Belen-Rubio, Lopez-Casas, Pedro P., Bruckheimer, Elizabeth, Calles-Blanco, Antonio, Sidransky, David, Hidalgo, Manuel
Publicat a J Clin Oncol (2012)

Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening

per LING, SHIZHANG, RETTIG, ELENI M., TAN, MARIETTA, CHANG, XIAOFEI, WANG, ZHIMING, BRAIT, MARIANA, BISHOP, JUSTIN A., FERTIG, ELANA J., CONSIDINE, MICHAEL, WICK, MICHAEL J., HA, PATRICK K.
Publicat a Int J Oncol (2016)

A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug

per Chen, Chen, Choudhury, Sujata, Wangsa, Darawalee, Lescott, Chamille J., Wilkins, Devan J., Sripadhan, Praathibha, Liu, Xuefeng, Wangsa, Danny, Ried, Thomas, Moskaluk, Christopher, Wick, Michael J., Glasgow, Eric, Schlegel, Richard, Agarwal, Seema
Publicat a Sci Rep (2017)

Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma

per Warner, Kristy A., Nör, Felipe, Acasigua, Gerson A., Martins, Manoela D., Zhang, Zhaocheng, McLean, Scott A., Spector, Matthew E., Chepeha, Douglas B., Helman, Joseph, Wick, Michael J., Moskaluk, Christopher A., Castilho, Rogerio M., Pearson, Alexander T., Wang, Shaomeng, Nör, Jacques E.
Publicat a Clin Cancer Res (2016)

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Res...

per Ferrarotto, Renata, Mitani, Yoshitsugu, Diao, Lixia, Guijarro, Irene, Wang, Jing, Zweidler-McKay, Patrick, Bell, Diana, William, William N., Glisson, Bonnie S., Wick, Michael J., Kapoun, Ann M., Patnaik, Amita, Eckhardt, Gail, Munster, Pamela, Faoro, Leonardo, Dupont, Jakob, Lee, J. Jack, Futreal, Andrew, El-Naggar, Adel K., Heymach, John V.
Publicat a J Clin Oncol (2017)

Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers

per Sudhan, Dhivya R., Guerrero-Zotano, Angel, Won, Helen, Ericsson, Paula González, Servetto, Alberto, Rosario, Mariela H., Ye, Dan, Lee, Kyung-min, Formisano, Luigi, Guo, Yan, Liu, Qi, Kinch, Lisa N., Brewer, Monica R., Dugger, Teresa, Koch, James, Wick, Michael J., Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Hanker, Ariella B., Arteaga, Carlos L.
Publicat a Cancer Cell (2020)

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

per Sudhan, Dhivya R., Guerrero-Zotano, Angel, Won, Helen, Ericsson, Paula González, Servetto, Alberto, Huerta-Rosario, Mariela, Ye, Dan, Lee, Kyung-min, Formisano, Luigi, Guo, Yan, Liu, Qi, Kinch, Lisa N., Brewer, Monica Red, Dugger, Teresa, Koch, James, Wick, Michael J., Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Hanker, Ariella B., Arteaga, Carlos L.
Publicat a Cancer Cell (2020)

An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma

per Drier, Yotam, Cotton, Matthew J., Williamson, Kaylyn E., Gillespie, Shawn M., Ryan, Russell J.H., Kluk, Michael J., Carey, Christopher D., Rodig, Scott J., Sholl, Lynette M, Afrogheh, Amir H., Faquin, William C., Queimado, Lurdes, Qi, Jun, Wick, Michael J., El-Naggar, Adel K., Bradner, James E., Moskaluk, Christopher A., Aster, Jon C., Knoechel, Birgit, Bernstein, Bradley E.
Publicat a Nat Genet (2016)

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

per Cocco, Emiliano, Carmona, F. Javier, Razavi, Pedram, Won, Helen H., Cai, Yanyan, Rossi, Valentina, Chan, Carmen, Cownie, James, Soong, Joanne, Toska, Eneda, Shifman, Sophie G, Sarotto, Ivana, Savas, Peter, Wick, Michael J., Papadopoulos, Kyriakos P., Moriarty, Alyssa, Cutler, Richard E., Avogadri-Connors, Francesca, Lalani, Alshad S., Bryce, Richard P., Chandarlapaty, Sarat, Hyman, David M., Solit, David B., Boni, Valentina, Loi, Sherene, Baselga, José, Berger, Michael F., Montemurro, Filippo, Scaltriti, Maurizio
Publicat a Sci Signal (2018)